Lie Ping Chen - Nanotechnology

Author Information

Dr. Lieping Chen is affiliated with the Department of Immunobiology at Yale University School of Medicine in New Haven, CT, USA. His research primarily focuses on immunotherapy and the immune response in cancer treatment. Dr. Chen’s work has been pivotal in understanding the mechanisms behind immune checkpoint inhibitors and their applications in oncology.

Research Contributions

Dr. Lieping Chen has significantly contributed to the field of cancer immunotherapy. His research includes the identification and targeting of critical components in the immune system to enhance anti-cancer responses. Some of his notable recent works involve studying the CSF1/CSF1R axis, PD-L1 copy number alterations, and the role of soluble CD137 as biomarkers in immunotherapy. Dr. Chen has also explored innovative treatment strategies such as targeting IL-21 and PD-1H to enhance T cell functionality and improve the efficacy of adoptive immunotherapy.

Aliases

Dr. Lieping Chen is also known by the following aliases:

Lieping Chen Lie Ping Chen Liepin Chen

Publication and Citation Metrics

Metric	Value
Total Citation Count	78,305
H-index	122
Total Number of Papers	513

Publications:

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

DOI: 10.1136/jitc-2021-003532

Year: 2022

Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?

DOI: 10.1016/j.jtho.2022.03.009

Year: 2022

Targeting the CSF1/CSF1R Axis is a Potential Treatment Strategy for Malignant Meningiomas.

DOI: 10.1093/neuonc/noab075

Year: 2021

Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

DOI: 10.1038/s41467-021-21241-0

Year: 2021

Ablation of T cell–associated PD-1H enhances functionality and promotes adoptive immunotherapy

DOI: 10.1172/jci.insight.148247

Year: 2021

An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP+ mononuclear cells and PDGF-BB secretion

DOI: 10.1038/s41413-021-00161-1

Year: 2021

A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy.

DOI: 10.1158/2159-8290.CD-20-0962

Year: 2021

Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.

DOI: 10.1093/jnen/nlaa152

Year: 2021

YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment

DOI: 10.1038/s41598-021-91623-3

Year: 2021

1204P Expression of cholinesterase is associated with prognosis and response to chemotherapy in advanced gastric cancer

DOI: 10.1016/j.annonc.2020.08.098

Year: 2020

How Does Nanophysics Impact Material Science?

How are Costs Evaluated?

Why is Innovation Important in Nanotechnology?

How Are Nanomaterials Used in Photovoltaics?

What are the Key Areas of Competition?

What are the Future Directions for Nanotechnology Regulation?

How Does Abinit Work?

What are the Challenges in Developing QSAR Models for Nanomaterials?

How Does Selective Precipitation Work?

How is Deep Learning Applied in Nanotechnology?

Partnered Content Networks

Relevant Topics